Rentschler Biotechnologie Extends Capacities for Mammalian Cell Culture Manufacturing
News Jun 24, 2008
Rentschler Biotechnologie, a full-service contract manufacturing organization (CMO) for the development and production of biopharmaceuticals in mammalian cells, started operation of a 2,500 L multi-process production suite.
Hence, Rentschler Biotechnologie now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 liters, allowing the production of material for clinical trials and for market supply.
The modern 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.
Using its modern GMP production suites, Rentschler Biotechnologie offers its customers comprehensive services “from gene to drug product”. It is able to develop tailored solutions for each customer through all phases of development and production. Due to its “preferred partnership” agreement with Boehringer Ingelheim, customers requiring higher production capacities than that offered by Rentschler, receive easy access to Boehringer’s large-scale bioreactor volumes of up to 15,000 L.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE